SignalXSignalX

ERAS Erasca, Inc.

Q3 2025 10-Q
Filed: Nov 12, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Erasca, Inc. Overview

Erasca, Inc. (ERAS) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 12, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • No new or changed risk factors reported versus 2024 10-K
  • • Clinical trial delays and regulatory approvals remain key operational risks impacting near-term milestones
+3 more insights

Quarterly Financial Summary
XBRL

Net Income

-$31M

▲ +1.9% YoY▲ +9.6% QoQ

ROE

-8.8%

Total Assets

$420M

EPS (Diluted)

$-0.11

▼ -57.1% YoY▲ +8.3% QoQ

Operating Cash Flow

-$22M

▲ +3.4% YoY▼ -5.5% QoQ

Source: XBRL data from Erasca, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Erasca, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.